Physician profile
Samir Derisavifard
NPI 1477997690
$5,693.49
in general payments reported to CMS, 2019-2025
13 companies · $3,858 in 2025
The $3,858 reported for 2025 was more than what 80% of Urogynecology and Reconstructive Pelvic Surgery (Urology) providers received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $459 · 2021: $315 · 2022: $176 · 2023: $497 · 2024: $388 · 2025: $3,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,243.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Femselect INC. | $3,926.80 | 2023-2025 | Enplace |
| Medtronic, INC. | $642.50 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $255.47 | 2020 | |
| Axonics, INC. | $236.79 | 2021-2024 | Bulkamid |
| Boston Scientific Corporation | $190.06 | 2020-2025 | Axonics, Bulkamid |
| Olympus America INC. | $150.00 | 2021 | |
| Coloplast Corp | $130.77 | 2020 | |
| Urovant Sciences INC | $45.26 | 2022 | |
| Astellas Pharma US INC | $27.78 | 2021 | |
| Valencia Technologies Corporation | $27.12 | 2025 | Ecoin Device Kit |
| Caldera Medical, INC | $24.07 | 2021 | |
| Antares Pharma, INC. | $18.75 | 2022 | |
| Pfizer INC. | $18.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Derisavifard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.